Genentech, Ipsen to Develop Sustained-Release Recombinant Human Growth Hormone

Genentech and Ipsen have executed a collaborative R&D agreement to develop sustained-release formulations of Genentech's recombinant human growth hormone [somatropin (rDNA origin)].

This R&D collaboration is in addition to a previous agreement signed in 2002 whereby Ipsen gained exclusive rights to market NutropinAq Pen throughout Europe and the rest of the world, excluding North America and Japan.

Nutropin AQ Pen for use with the Nutropin AQ Pen cartridge was cleared for marketing by the FDA in April 2002 and obtained marketing authorization under the trade name NutropinAq Pen from the European Medicines Agency in March 2004. Ipsen has already launched NutropinAq Pen in 12 European countries.